

2024 Educational Forum IMMERSE, EXPLORE, SOAR!

Welcome to Day Three of the 2024 Educational Forum

May 3-5, 2024
Hyatt Regency Lake Washington



Thank You to Our 2024 Ed Forum Sponsors







Johnson&Johnson








Laurie Rude-Betts

Founder
Ben Rude Heritage Society
(BRHS)





Ben Rude, IWMF President 2000-2005



"A PERSON'S LIFE IS MEASURED BY THE EFFORT MADE FOR THE BENEFIT OF OTHERS"

BEN RUDEIWMF PRESIDENT2000-2005



What is the Ben Rude Heritage Society (BRHS)?

- Recognizes those who have included the IWMF in their estate planning
- Since 2008, 45 bequests totaling over \$4M received with total commitments of over \$12M
- 170 current members
- Gifts ranged between \$100 to \$1M
- Every single gift makes a difference to the IWMF



How Can I Help? It's easy!

- •Designate the IWMF as a beneficiary of your IRA, 40l(k), 403(b), profit-sharing plan or tax-deferred plan
- •Include the IWMF as a beneficiary of life insurance policies



Ben Rude Heritage Society

New Members 1/1/2023 through 4/30/24

Jane Ballard In Honor of Shirley Ganse

Ronald and Mary Jane Branscome

Charmaine DeFrance

Peter DeNardis

Richard and Jean Heinz

Jennifer Hoegerman

Scott Hollis

Kim Jackman

Elena Justice

Ann Wadkins Kallam
Sandra Eileen Kohlhauff
Barbara Qualley
Andy Ruland
Robin and Ronald Rutter
Karen Elizabeth Senecal
Susan Sherwin
Joyce Ann Skeggs
The White Family Trust
Arthur Winter





2024 Educational Forum IMMERSE, EXPLORE, SOAR!



FreeWill makes estate planning warm, intuitive, and totally free.

So you can more easily care for the people and causes you love.





2024 Educational Forum IMMERSE, EXPLORE, SOAR!

Accelerate the Cure Campaign \$25M over 5 years

Having a rare disease, it's up to us!





IWMF Research History Highlights

- 1943 Dr. Waldenström identifies WM
- 2002 IWWM2 defines what WM is
- 2011 MYD88 discovered; controls a druggable pathway (BTK)
- 2012 First breakthrough therapy designation in all of cancer for WM for ibrutinib
- 2015 Ibrutinib approved by FDA for WM
- 2021 Zanubrutinib approved for WM



Three Opportunity Funds



A: Research Portfolio


B: Multi-Institutional Network— **Clinical Trials (WM-NET)**

C: Next Generation Researcher





Fund A: Research Portfolio




International Scientific Advisory Committee (21 WM experts)

Proposals meet NIH-Standards: Potential for timely game-changing impact



Fund B: Institutional Clinical Trails



Rare disease challenge

Clinical trials required

WM-NET: A first





Fund C: Next Generation Researchers

- **❖** Add bright minds— to search for a cure
- Junior faculty & post-doctoral
- **❖** Robert A. Kyle Awards—2-years; plasma cell disorder research under WM mentors



Dr. Treon Video: Is a Cure Possible?









\$25 Million

We seek 100% giving

Talk with us about major investment opportunities.



